問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Principal Investigator

林家齊

List

270Cases

2020-03-01 - 2022-12-30

Phase I

A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination With Pembrolizumab in Participants With KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma

  • Condition/Disease

    Advanced/Metastatic solid tumors

  • Test Drug

    V941 (mRNA-5671)/ Pembrolizumab

Participate Sites
3Sites

Recruiting3Sites

2013-12-18 - 2019-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2014-10-01 - 2020-12-01

Phase III

A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer

  • Condition/Disease

    Recurrent or Progressive Metastatic Urothelial Cancer

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
5Sites

Terminated5Sites

2018-01-15 - 2019-08-21

Phase III

A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients Who Have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303)

  • Condition/Disease

    Urothelial Cancer

  • Test Drug

    Pembrolizumab ; Epacadostat

Participate Sites
5Sites

Terminated5Sites

2018-01-15 - 2020-12-25

Phase III

A Phase 3 Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) or Placebo in Participants With Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

  • Condition/Disease

    Urothelial Cancer

  • Test Drug

    Keytruda / Epacadostat

Participate Sites
6Sites

Terminated5Sites

2017-11-01 - 2022-06-27

Phase III

A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)

  • Condition/Disease

    Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC)

  • Test Drug

    Pembrolizumab; Epacadostat

Participate Sites
6Sites

Terminated6Sites

2015-04-15 - 2019-12-31

Phase II

A Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer

  • Condition/Disease

    Advanced/Unresectable or Metastatic Urothelial Cancer

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
3Sites

Terminated2Sites

2015-12-01 - 2026-12-31

Phase II

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
8Sites

Recruiting8Sites

2019-06-01 - 2025-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2015-09-01 - 2018-12-31

Phase II

A Phase 1b/2 Study of MEDI4736 in Combination with Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects with Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

  • Condition/Disease

    Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

  • Test Drug

    Durvalumab (MEDI4736), Tremelimumab

Participate Sites
3Sites

Terminated3Sites

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

1 19 20 21 22 23 27
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB